BG64326B1 - Използване на едномерен ядреномагнитен резонанс за идентифициране на лиганди с таргет биомолекули - Google Patents

Използване на едномерен ядреномагнитен резонанс за идентифициране на лиганди с таргет биомолекули Download PDF

Info

Publication number: BG64326B1
Authority: BG; Bulgaria
Prior art keywords: target molecule; compound; compounds; ligand; ligands
Prior art date: 1997-04-18

Application number

BG103856A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG103856A (en

Inventor

Stephen W. Fesik

Philip J. Hajduk

Edward T. Olejniczak

Original Assignee

Abbott Laboratories

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-18

Filing date

1999-11-04

Publication date

2004-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25291882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG64326(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-11-04 Application filed by Abbott Laboratories filed Critical Abbott Laboratories

2000-07-31 Publication of BG103856A publication Critical patent/BG103856A/xx

2004-09-30 Publication of BG64326B1 publication Critical patent/BG64326B1/bg

Links

239000003446 ligand Substances 0.000 title claims abstract description 156
238000005481 NMR spectroscopy Methods 0.000 title claims description 17
150000001875 compounds Chemical class 0.000 claims abstract description 157
238000000034 method Methods 0.000 claims abstract description 77
239000000203 mixture Substances 0.000 claims abstract description 55
238000009792 diffusion process Methods 0.000 claims abstract description 21
230000000694 effects Effects 0.000 claims abstract description 6
238000000655 nuclear magnetic resonance spectrum Methods 0.000 claims description 23
238000012216 screening Methods 0.000 claims description 18
238000012360 testing method Methods 0.000 claims description 15
229920001184 polypeptide Polymers 0.000 claims description 14
102000004196 processed proteins & peptides Human genes 0.000 claims description 14
108090000765 processed proteins & peptides Proteins 0.000 claims description 14
150000003384 small molecules Chemical class 0.000 claims description 13
238000002360 preparation method Methods 0.000 claims description 3
GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims description 2
102000014914 Carrier Proteins Human genes 0.000 claims description 2
108091008324 binding proteins Proteins 0.000 claims description 2
230000004071 biological effect Effects 0.000 claims description 2
102000039446 nucleic acids Human genes 0.000 claims description 2
108020004707 nucleic acids Proteins 0.000 claims description 2
150000007523 nucleic acids Chemical class 0.000 claims description 2
102000040430 polynucleotide Human genes 0.000 claims description 2
108091033319 polynucleotide Proteins 0.000 claims description 2
238000003786 synthesis reaction Methods 0.000 claims description 2
102000004190 Enzymes Human genes 0.000 claims 1
108090000790 Enzymes Proteins 0.000 claims 1
230000004962 physiological condition Effects 0.000 claims 1
238000001228 spectrum Methods 0.000 abstract description 81
238000004519 manufacturing process Methods 0.000 abstract description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
239000000126 substance Substances 0.000 description 18
102000004169 proteins and genes Human genes 0.000 description 16
108090000623 proteins and genes Proteins 0.000 description 16
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
238000002474 experimental method Methods 0.000 description 14
229940125904 compound 1 Drugs 0.000 description 12
239000000243 solution Substances 0.000 description 11
238000003556 assay Methods 0.000 description 8
230000008901 benefit Effects 0.000 description 8
239000000872 buffer Substances 0.000 description 8
238000013461 design Methods 0.000 description 7
125000005647 linker group Chemical group 0.000 description 7
239000011780 sodium chloride Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
230000008859 change Effects 0.000 description 6
239000011550 stock solution Substances 0.000 description 5
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
239000002547 new drug Substances 0.000 description 4
230000008569 process Effects 0.000 description 4
230000004044 response Effects 0.000 description 4
230000003595 spectral effect Effects 0.000 description 4
238000004611 spectroscopical analysis Methods 0.000 description 4
125000003118 aryl group Chemical group 0.000 description 3
238000000685 Carr-Purcell-Meiboom-Gill pulse sequence Methods 0.000 description 2
OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000009471 action Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
238000013459 approach Methods 0.000 description 2
239000012062 aqueous buffer Substances 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
230000009918 complex formation Effects 0.000 description 2
238000010494 dissociation reaction Methods 0.000 description 2
230000005593 dissociations Effects 0.000 description 2
239000003814 drug Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000009510 drug design Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
238000002825 functional assay Methods 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000005259 measurement Methods 0.000 description 2
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002424 x-ray crystallography Methods 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
150000007824 aliphatic compounds Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
238000004590 computer program Methods 0.000 description 1
238000012937 correction Methods 0.000 description 1
238000005100 correlation spectroscopy Methods 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
239000012467 final product Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
150000002605 large molecules Chemical class 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000003607 modifier Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000004899 motility Effects 0.000 description 1
238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
238000010916 retrosynthetic analysis Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
238000010183 spectrum analysis Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000012546 transfer Methods 0.000 description 1
239000012224 working solution Substances 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
- G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
- G01N24/087—Structure determination of a chemical compound, e.g. of a biomolecule such as a protein
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
- G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G—PHYSICS
- G01—MEASURING; TESTING
- G01V—GEOPHYSICS; GRAVITATIONAL MEASUREMENTS; DETECTING MASSES OR OBJECTS; TAGS
- G01V3/00—Electric or magnetic prospecting or detecting; Measuring magnetic field characteristics of the earth, e.g. declination, deviation
- G01V3/14—Electric or magnetic prospecting or detecting; Measuring magnetic field characteristics of the earth, e.g. declination, deviation operating with electron or nuclear magnetic resonance
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit

Landscapes

Life Sciences & Earth Sciences (AREA)
Physics & Mathematics (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
High Energy & Nuclear Physics (AREA)
General Physics & Mathematics (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Analytical Chemistry (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Pathology (AREA)
Urology & Nephrology (AREA)
Medicinal Chemistry (AREA)
Food Science & Technology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Bioinformatics & Computational Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Condensed Matter Physics & Semiconductors (AREA)
Spectroscopy & Molecular Physics (AREA)
Crystallography & Structural Chemistry (AREA)
Environmental & Geological Engineering (AREA)
Geology (AREA)
Remote Sensing (AREA)
General Life Sciences & Earth Sciences (AREA)
Geophysics (AREA)
Investigating Or Analysing Biological Materials (AREA)
Magnetic Resonance Imaging Apparatus (AREA)
Peptides Or Proteins (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BG103856A 1997-04-18 1999-11-04 Използване на едномерен ядреномагнитен резонанс за идентифициране на лиганди с таргет биомолекули BG64326B1 (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/844,124 US6043024A (en)	1997-04-18	1997-04-18	Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules
PCT/US1998/007907 WO1998048264A1 (en)	1997-04-18	1998-04-17	Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules

Publications (2)

Publication Number	Publication Date
BG103856A BG103856A (en)	2000-07-31
BG64326B1 true BG64326B1 (bg)	2004-09-30

Family

ID=25291882

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG103856A BG64326B1 (bg)	1997-04-18	1999-11-04	Използване на едномерен ядреномагнитен резонанс за идентифициране на лиганди с таргет биомолекули

Country Status (28)

Country	Link
US (1)	US6043024A (es)
EP (1)	EP0975954B2 (es)
JP (1)	JP2002507277A (es)
KR (1)	KR100542420B1 (es)
CN (1)	CN1225648C (es)
AR (1)	AR004651A1 (es)
AT (1)	ATE259061T1 (es)
AU (1)	AU7138098A (es)
BG (1)	BG64326B1 (es)
BR (1)	BR9808079A (es)
CA (1)	CA2286795C (es)
CO (1)	CO5060446A1 (es)
CZ (1)	CZ297275B6 (es)
DE (1)	DE69821475T3 (es)
DK (1)	DK0975954T4 (es)
ES (1)	ES2215296T5 (es)
HU (1)	HU228433B1 (es)
IL (1)	IL131726A0 (es)
NO (1)	NO995078L (es)
NZ (1)	NZ337126A (es)
PL (1)	PL194184B1 (es)
PT (1)	PT975954E (es)
SI (1)	SI0975954T1 (es)
SK (1)	SK285411B6 (es)
TR (1)	TR199902167T2 (es)
TW (1)	TW574502B (es)
WO (1)	WO1998048264A1 (es)
ZA (1)	ZA982919B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI982069A7 (fi) *	1996-03-29	1998-11-10	Lawrence Berkeley Nat Laboratory	NMR:n ja MRI:n tehostaminen hyperpolaroitujen jalokaasujen läsnä olles sa
US20030143757A1 (en) *	1997-06-13	2003-07-31	Jonathan Moore	Methods for identifying drug cores
US6111066A (en)	1997-09-02	2000-08-29	Martek Biosciences Corporation	Peptidic molecules which have been isotopically substituted with 13 C, 15 N and 2 H in the backbone but not in the sidechains
US6344330B1 (en)	1998-03-27	2002-02-05	The Regents Of The University Of California	Pharmacophore recombination for the identification of small molecule drug lead compounds
US7501236B1 (en) *	1998-12-30	2009-03-10	Ge Healthcare Limited	NMR spectroscopic in vitro assay using hyperpolarization
US6333149B1 (en)	1999-06-04	2001-12-25	Triad Biotechnology, Inc.	NMR-solve method for rapid identification of bi-ligand drug candidates
CA2383559A1 (en) *	1999-08-23	2001-03-01	Polaris Pharmaceuticals, Inc.	Inhibitors of binding between proteins and macromolecular ligands
US6677160B1 (en)	1999-09-29	2004-01-13	Pharmacia & Upjohn Company	Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules
US6764858B2 (en)	1999-09-29	2004-07-20	Pharmacia & Upjohn Company	Methods for creating a compound library
WO2001079852A2 (en) *	2000-04-17	2001-10-25	Pharmacia & Upjohn Company	Nmr-methods for indentifying sites in papillomavirus e2 protein
US7146277B2 (en) *	2000-06-13	2006-12-05	James H. Prestegard	NMR assisted design of high affinity ligands for structurally uncharacterized proteins
US7061237B2 (en) *	2000-07-13	2006-06-13	The Regents Of The University Of California	Remote NMR/MRI detection of laser polarized gases
US20030165431A1 (en) *	2000-07-13	2003-09-04	The Regents Of The University Of California	Method for detecting macromolecular conformational change and binding information
WO2002022154A2 (en) *	2000-09-13	2002-03-21	Praecis Pharmaceuticals Incorporated	Pharmaceutical compositions for sustained drug delivery
JP5129424B2 (ja) *	2000-09-27	2013-01-30	ユニヴェルシテイトレイデン	リガンドの発見または薬物スクリーニング手段としてのｎｍｒ利用法
CA2432924A1 (en) *	2000-12-21	2002-06-27	Triad Therapeutics, Inc.	Sea-trosy and related methods
GB0031566D0 (en) *	2000-12-22	2001-02-07	Mets Ometrix	Methods for spectral analysis and their applications
US20030092027A1 (en) *	2001-06-01	2003-05-15	Luciano Mueller	Nuclear magnetic resonance method for identifying ligands to target compounds
WO2003018631A2 (en) *	2001-08-27	2003-03-06	Novartis Ag	Nogo receptor homologues and their use
US7653490B2 (en)	2001-09-10	2010-01-26	Triad Liquidating Company LLC	Nuclear magnetic resonance assembly of chemical entities
EP1440091A1 (en) *	2001-10-22	2004-07-28	Novartis AG	Nogo receptor homologues and their use
WO2003040400A2 (en) *	2001-11-06	2003-05-15	Message Pharmaceuticals, Inc.	Methods for detecting and quantifying binding and inhibition of binding of species to nucleic acids
KR100888805B1 (ko) *	2002-06-14	2009-03-16	크리스탈지노믹스(주)	특정 아미노산이 표지된 단백질과 1ｄｎｍｒ 기법을이용하여 단백질의 활성 부위에 결합하는 화합물을검색하는 방법
KR100901309B1 (ko) *	2002-06-15	2009-06-09	크리스탈지노믹스(주)	단백질의 활성 부위에 결합하는 화합물을 선별하는 방법
NO20025738D0 (no) *	2002-11-29	2002-11-29	Amersham Health As	Metode
US20070184455A1 (en) *	2003-05-16	2007-08-09	Cheryl Arrowsmith	Evaluation of spectra
US7595170B2 (en) *	2004-08-05	2009-09-29	Modrovich Ivan E	Apparatus and method for measuring concentrations of molecules through a barrier
US8933209B2 (en)	2006-04-26	2015-01-13	Abbvie Inc.	Dep2 and its uses in major depressive disorder and other related disorders
US20070256148A1 (en) *	2006-04-26	2007-11-01	Katz David A	DEP2 and its uses in major depressive disorder and other related disorders
FR2954830A1 (fr) *	2009-12-31	2011-07-01	Nmrtec	Methode d'analyse comparative par resonance magnetique nucleaire
CN108152513B (zh)	2011-09-29	2020-07-24	西雅图基因公司	蛋白偶联的试剂化合物的整体分子量测定
CN102507627B (zh) *	2011-11-14	2014-10-01	中国科学院武汉物理与数学研究所	一种高通量筛选药物的核磁共振方法
US9678185B2 (en)	2013-03-15	2017-06-13	Pepsico, Inc.	Method and apparatus for measuring physico-chemical properties using a nuclear magnetic resonance spectrometer
CN104198517B (zh) *	2014-09-23	2017-02-08	中国科学院昆明植物研究所	联合使用不同核的一维核磁共振混合物定量方法
CN104897826B (zh) *	2015-06-16	2016-06-22	广西师范大学	一种用于细胞原位检测小分子化合物与靶蛋白相互作用的方法
CN107328804B (zh) *	2017-07-21	2019-02-05	中国科学院山西煤炭化学研究所	一种甘油加氢反应混合物的核磁共振检测方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4789832A (en) *	1987-01-14	1988-12-06	Jeol Ltd.	Three-dimensional NMR spectroscopy
JPH05503691A (ja) *	1989-12-29	1993-06-17	ユニバーシティ・テクノロジーズ・インターナショナル・インコーポレイテッド	アゴニストおよびアンタゴニストを含む生物学的に活性なリガンドの３次構造モデルの設計方法およびアンギオテンシンに基づいた新規合成アンタゴニスト
US5270163A (en) *	1990-06-11	1993-12-14	University Research Corporation	Methods for identifying nucleic acid ligands
US5698401A (en) *	1995-11-14	1997-12-16	Abbott Laboratories	Use of nuclear magnetic resonance to identify ligands to target biomolecules

1997
- 1997-04-18 US US08/844,124 patent/US6043024A/en not_active Expired - Lifetime
1998
- 1998-03-11 TW TW87103594A patent/TW574502B/zh not_active IP Right Cessation
- 1998-04-06 ZA ZA982919A patent/ZA982919B/xx unknown
- 1998-04-15 CO CO98020602A patent/CO5060446A1/es unknown
- 1998-04-17 CA CA2286795A patent/CA2286795C/en not_active Expired - Fee Related
- 1998-04-17 CN CNB988042711A patent/CN1225648C/zh not_active Expired - Fee Related
- 1998-04-17 DE DE69821475T patent/DE69821475T3/de not_active Expired - Lifetime
- 1998-04-17 NZ NZ337126A patent/NZ337126A/en not_active IP Right Cessation
- 1998-04-17 ES ES98918461T patent/ES2215296T5/es not_active Expired - Lifetime
- 1998-04-17 AR ARP980101800A patent/AR004651A1/es unknown
- 1998-04-17 HU HU0003956A patent/HU228433B1/hu not_active IP Right Cessation
- 1998-04-17 AT AT98918461T patent/ATE259061T1/de active
- 1998-04-17 DK DK98918461T patent/DK0975954T4/da active
- 1998-04-17 CZ CZ0368399A patent/CZ297275B6/cs not_active IP Right Cessation
- 1998-04-17 EP EP98918461A patent/EP0975954B2/en not_active Expired - Lifetime
- 1998-04-17 TR TR1999/02167T patent/TR199902167T2/xx unknown
- 1998-04-17 JP JP54622898A patent/JP2002507277A/ja active Pending
- 1998-04-17 KR KR1019997009544A patent/KR100542420B1/ko not_active Expired - Fee Related
- 1998-04-17 BR BR9808079-2A patent/BR9808079A/pt not_active IP Right Cessation
- 1998-04-17 PT PT98918461T patent/PT975954E/pt unknown
- 1998-04-17 PL PL98336299A patent/PL194184B1/pl unknown
- 1998-04-17 SI SI9830634T patent/SI0975954T1/xx unknown
- 1998-04-17 IL IL13172698A patent/IL131726A0/xx not_active IP Right Cessation
- 1998-04-17 SK SK1416-99A patent/SK285411B6/sk not_active IP Right Cessation
- 1998-04-17 AU AU71380/98A patent/AU7138098A/en not_active Abandoned
- 1998-04-17 WO PCT/US1998/007907 patent/WO1998048264A1/en not_active Ceased
1999
- 1999-10-18 NO NO995078A patent/NO995078L/no not_active Application Discontinuation
- 1999-11-04 BG BG103856A patent/BG64326B1/bg unknown

Also Published As

Publication number	Publication date
HK1027158A1 (en)	2001-01-05
HUP0003956A2 (en)	2001-03-28
CN1252868A (zh)	2000-05-10
HU228433B1 (en)	2013-03-28
TW574502B (en)	2004-02-01
HUP0003956A3 (en)	2002-04-29
NO995078L (no)	1999-12-06
US6043024A (en)	2000-03-28
KR20010006454A (ko)	2001-01-26
BR9808079A (pt)	2000-03-08
EP0975954A1 (en)	2000-02-02
EP0975954B2 (en)	2009-03-18
AU7138098A (en)	1998-11-13
BG103856A (en)	2000-07-31
CZ9903683A3 (cs)	2001-02-14
CO5060446A1 (es)	2001-07-30
ES2215296T3 (es)	2004-10-01
ZA982919B (en)	1998-10-12
DE69821475D1 (de)	2004-03-11
DK0975954T3 (da)	2004-06-07
WO1998048264A1 (en)	1998-10-29
SK141699A3 (en)	2000-06-12
CN1225648C (zh)	2005-11-02
NO995078D0 (no)	1999-10-18
DE69821475T2 (de)	2004-11-25
PT975954E (pt)	2004-06-30
DE69821475T3 (de)	2009-07-23
PL194184B1 (pl)	2007-05-31
CA2286795C (en)	2010-06-29
DK0975954T4 (da)	2009-05-18
TR199902167T2 (xx)	2000-07-21
PL336299A1 (en)	2000-06-19
KR100542420B1 (ko)	2006-01-11
ATE259061T1 (de)	2004-02-15
CZ297275B6 (cs)	2006-10-11
SI0975954T1 (en)	2004-08-31
EP0975954B1 (en)	2004-02-04
IL131726A0 (en)	2001-03-19
CA2286795A1 (en)	1998-10-29
ES2215296T5 (es)	2009-07-06
JP2002507277A (ja)	2002-03-05
SK285411B6 (sk)	2007-01-04
NZ337126A (en)	2001-05-25
AR004651A1 (es)	1999-03-10

Publication	Publication Date	Title
BG64326B1 (bg)	2004-09-30	Използване на едномерен ядреномагнитен резонанс за идентифициране на лиганди с таргет биомолекули
Lucas et al.	2004	Measuring ligand‐protein binding using NMR diffusion experiments
Dalvit et al.	2002	High-throughput NMR-based screening with competition binding experiments
Tengel et al.	2004	Use of 19F NMR spectroscopy to screen chemical libraries for ligands that bind to proteins
Wang et al.	2014	Recent advances in protein NMR spectroscopy and their implications in protein therapeutics research
DE69613146T3 (de)	2007-06-14	Verwendung von kernspinresonanz zur bestimmung von liganden für zielbiomoleküle
Wang et al.	2020	Amplification of nuclear Overhauser effect signals by hyperpolarization for screening of ligand binding to immobilized target proteins
Park et al.	2023	Methods for analyzing the coordination and aggregation of metal–amyloid-β
Dalvit et al.	2002	Competition binding experiments for rapidly ranking lead molecules for their binding affinity to human serum albumin
Lowery et al.	2003	Applications of laser-polarized 129Xe to biomolecular assays
Dey et al.	2020	Correction of systematic bias in single molecule photobleaching measurements
Ishima	2015	Protein-inhibitor interaction studies using NMR
CA2388216A1 (en)	2001-05-10	Use of double-quantum 1h-nmr spectroscopy for the identification of ligands interacting with target biomolecules
KR20110125726A (ko)	2011-11-22	핵자기공명 분광기를 이용한 동등생물의약품 구조의 비교 평가 방법
Ross et al.	2003	Automation of biomolecular NMR screening
AU772620B2 (en)	2004-05-06	Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules
JP5129424B2 (ja)	2013-01-30	リガンドの発見または薬物スクリーニング手段としてのｎｍｒ利用法
CA2400867A1 (en)	2001-08-30	Method of screening compounds for biological activity
HK1027158B (en)	2004-11-12	Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules
Marincin et al.	2023	New approaches to track chemoenzymatic loading reactions of NRPS carrier protein domains using NMR
MXPA99009558A (es)	2000-07-01	Uso de resonancia magnetica nuclear de una dimension para identificar ligandos para moleculas objetivo
Castiglione	2011	NMR analysis of unnatural amino acids in natural antibiotics
IL149514A (en)	2004-06-01	Use of two dimensional <15>n/<1>n nmr correlation spectroscopy in a process for designing high-affinity ligands to target biomolecules